MedTrace Logo

MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

NCT00135863 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-05-21

No results posted yet for this study

Summary

Patients with end stage renal disease (ESRD) who use peritoneal dialyses with Physioneal(R) (Baxter A/S, Denmark) were allocated to inject either placebo or tinzaparin daily into the morning dialysis bag. Active medication, as well as placebo, was added for three months separated by a one month washout period. At the beginning and end of each treatment period peritoneal equilibrations tests (PE-tests), Kt/V, blood and dialysate samples were analyzed. We, the researchers at Ribe County Hospital, set out to examine inflammation (local and systemic), nutrition and ultrafiltration.

Conditions

Interventions

DRUG

tinzaparin

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Coloplast A/S

    collaborator INDUSTRY

  • Ribe County Hospital

    lead OTHER

Principal Investigators

  • Robert S Petersen, MD · Ribe County Hospital, Department of Nephrology

  • Mikkel B Rasmussen, MD · Ribe County Hospital, Department of Nephrology

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2005-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00135863 on ClinicalTrials.gov